- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
New Dell Healthcare CMO Comments on Company's Genomics Focus
Dell Healthcare and Life Sciences (NASDAQ:DELL) announced a new CMO on Monday. Dr. Nick van Terheyden will take over the position, a month after stepping down as CMIO at Nuance Communications.
Dell Healthcare and Life Sciences (NASDAQ:DELL) announced a new CMO on Monday. Dr. Nick van Terheyden will take over the position, a month after stepping down as CMIO at Nuance Communications.
According to an article published on MedCityNews:
Plano, Texas-based Dell Healthcare & Life Sciences has groups focused on mobile health, cloud computing, cybersecurity and genomics, among other areas. Dell’s healthcare cloud currently stores about 9 billion medical images, van Terheyden said, and most are tied to analytics systems.
In the area of genomics, Dell is partnering with the Translational Genomics Research Institute (TGen) on what the company says is the first FDA-approved personalized medicine trial for pediatric cancer.
Van Terheyden, a supporter of genomics research, states:
I’m very much in the Eric Topol camp of where things are going.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â